Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Rituximab is a monoclonal antibody used in the treatment of B-cell malignancies. Infusion reactions are common during the first exposure but decrease with subsequent infusions. We here present our experience with a protocol for a 30-minute intravenous infusion of rituximab (SpeedR) to patients who have previously tolerated a 90-minute rituximab infusion. All patients were premedicated with 10 mg cetirizine and 1 g paracetamol (steroids were only given when part of a concomitant chemotherapy regimen). In this cohort 268 patients received a total of 940 intravenous 30-minute infusions with only nine patients having adverse reactions (all grade 1-2) which required little or no treatment. Out of the nine patients with reactions, seven were planned for more rituximab treatment and all of them could later continue with 30-minute rituximab infusions. We conclude that 30-minute rituximab infusions are a safe and efficient way to optimize workflow in the outpatient clinic and to give cost-effective treatment to lymphoma patients.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1007/s00277-025-06521-9 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Comparative Bioequivalence Study of 2 Clevidipine Formulations in Healthy Chinese participants: A Single-Dose, 2-Period Crossover Trial.
Clin Pharmacol Drug Dev
August 2025
National Drug Clinical Trial Institution of West China Second Hospital, Sichuan University, Chengdu, China.
Clevidipine emulsion is an intravenous antihypertensive agent indicated for acute blood pressure control when oral therapies are contraindicated or ineffective. To address this gap in availability, a randomized, 2-period, 2-sequence crossover trial was conducted to evaluate the bioequivalence and safety of a generic clevidipine emulsion versus the reference product in 32 healthy Chinese adults. Participants received a 30-minute intravenous infusion of 3 mg of clevidipine (test or reference formulation) in each study period, with serial blood samples collected from the contralateral arm relative to the infusion site for pharmacokinetic analysis.
View Article and Find Full Text PDFPrecision-Engineered Cobalt-doped Iron Oxide Nanoparticles: From Octahedron Seeds to Cubical Bipyramids for Enhanced Magnetic Hyperthermia.
Adv Funct Mater
March 2025
Department of Pharmaceutical Sciences, College of Pharmacy, Oregon State University, 2730 SW Moody Avenue, Portland, Oregon, 97201, USA.
Despite notable advancements, the significantly improved yet suboptimal heating efficiency of current magnetic nanoparticles hinders the effectiveness of systemically delivered magnetic hyperthermia in reducing tumor size or halting growth. Addressing this challenge, the seed-and-growth thermal decomposition method has been developed to synthesize cobalt-doped iron oxide nanoparticles featuring a cubical bipyramid morphology and consisting of both magnetite and maghemite phases within their nanostructure. They possess an exceptional specific absorption rate of 14,686 ± 396 W g Fe, inducing a temperature rise of 3.
View Article and Find Full Text PDFA 30-minute intravenous infusion of rituximab is safe and cost-effective (SpeedR).
Ann Hematol
July 2025
Division of Hematology, Department of Medicine, Huddinge, Karolinska Institutet, Stockholm, Sweden.
Rituximab is a monoclonal antibody used in the treatment of B-cell malignancies. Infusion reactions are common during the first exposure but decrease with subsequent infusions. We here present our experience with a protocol for a 30-minute intravenous infusion of rituximab (SpeedR) to patients who have previously tolerated a 90-minute rituximab infusion.
View Article and Find Full Text PDFSafety of accelerated infusion of nivolumab and pembrolizumab.
Eur J Cancer
May 2025
Department of Medical Oncology, Radboudumc, Nijmegen, the Netherlands; Department of Medical Oncology, Zuyderland MC, Sittard-Geleen, the Netherlands.
Nivolumab and pembrolizumab are checkpoint inhibitors targeting programmed cell death-1, used for several types of cancer. The increased use of these drugs and the growing number of cancer patients place a significant burden on the hospital ward capacity. Safely reducing the infusion time of immune checkpoint inhibitors could improve capacity.
View Article and Find Full Text PDFComparative effectiveness of small group practice and 3D VR simulation on nursing students' PIVC skills, flow state, and learning satisfaction: A quasi-experimental study.
Nurse Educ Today
July 2025
College of Nursing, Eulji University, Seongnam campus, Republic of Korea. Electronic address:
Background: PIVC (Peripheral intravenous catheterization) skills are highly challenging techniques frequently used in clinical settings. To prevent complications from intravenous catheterisation and to ensure patient safety, it is necessary to identify effective training methods.
Aim: This study aimed to evaluate the educational effects of 3D VR simulation practice versus small group practice on nursing students' skill performance, learning satisfaction, and flow state.